Ricardo A. Fernandes
COI Group Leader
The main objective of our research group is to identify key functional aspects affecting anti-tumor responses by T cells. To do this, we use protein engineering, guided by structural and signaling information, to generate novel molecules that allow us to explore and interrogate key aspects of receptor signaling and T cell function. We are currently focusing our efforts in developing molecules to overcome “inhibitory” signaling by immune checkpoint receptors and to enhance signaling by the T-cell receptor.
Ricardo Fernandes recently joined CAMS Oxford Institute coming from Stanford where he developed novel molecules to effectively shut down signaling by immune receptors such as PD-1.
Recent publications
Patch deconvolution for Fourier light-field microscopy.
Journal article
Fu B. et al, (2026), Biophys J, 125, 1305 - 1314
Targeting immune cells in the aged brain reveals that engineered cytokine IL-10 enhances neurogenesis and improves cognition.
Journal article
Navarro Negredo P. et al, (2026), Immunity, 59, 458 - 476.e13
Uncovering structural determinants of peptide recognition by public and private T-cell receptors.
Preprint
Akıl C. et al, (2025)
Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis.
Journal article
Pinho MP. et al, (2025), Cell Rep Med, 6
Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review.
Journal article
Dewaele L. and Fernandes RA., (2025), Immunother Adv, 5